Company
VolitionRx
NYSE:VNRX
VolitionRx Limited is a multi-national epigenetics company developing simple, easy-to-use, cost-effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients but also to improve their quality of life. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics. Volition's research and development activities are centered in Belgium, with additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic products to market.
89 stories
Q Battery Metals stock jumps on exploration update plus more daily small cap movers
Lithium exploration plans powered shares of Q Battery Metals Corp Thursday plus other big percentage movers on news from the small and micro cap space
VolitionRX ends Q3 with $16.4 million cash, moves from R&D to commercial cancer screening company
"This quarter, and subsequent to quarter end, I am proud we have executed yet another global supply agreement with a market leader in pet healthcare," said CEO Cameron Reynolds
VolitionRx teams up with leading French veterinary group to assess potential of cancer screening technology
The non-interventional study will be overseen by Dr Jérôme Benoit, the clinical director of Oncovet in Lille
Volition to use Nu.Q test in international study on the early detection of lung cancer
“We know that screening saves lives and there is a real unmet need for lung cancer screening globally," said COO Gael Forterre
VolitionRX launches Nu.Q cancer-screen test for dogs in US, preps for European launch by Heska
“It is another key milestone for us, as we press ahead with our aim to ensure as many veterinarians as possible can access our Nu.Q vet cancer screening test for the pets and pet owners who trust them,” said VolitionRx veterinarian diagnost
VolitionRX inks global agreement to provide Nu.Q cancer detection test to veterinarians
A peer-reviewed clinical study showed the Nu.Q blood test detected 76% of systemic cancers in animals
VolitionRx adds marketing executive Mickie Henshall to its board of directors
Henshall told Volition shareholders that she believes there is enormous potential for the company to revolutionize the diagnosis of life-altering diseases through its Nu.Q product portfolio
VolitionRx ends 2Q with $16.7M, secures further funding to advance trials and commercialization efforts
The epigenetics company had a busy quarter that saw it receive a CE Mark for its Nu.Q Netosis test in Europe and reveal new clinical studies for NETs in the US
VolitionRx says it will participate in US clinical study for NETs in sepsis cancer patients
“Cancer patients have a weakened immune system and have a 10 times higher likelihood of developing sepsis and are also more likely to die if they develop it,” VolitionRx chief scientific officer Dr Jake Micallef said
VolitionRx appoints DXOCRO to undertake development and clinical validation studies for its Nu.Q product portfolio in the US
“DXOCRO will spearhead both our clinical product development and our regulatory program in the United States, and seek to establish clinical utility for our Nu.Q products,” said Sharon Ballesteros, US head of quality and development process
VolitionRx awarded $1.5 million in non-dilutive funding
The company said the loan from Namur Invest will fund an early access program for Volition's Nu.Q product portfolio at key sites across the EU, UK, and the United States
VolitionRx Limited inks R&D collaboration deals with Xenetic Biosciences and Salarius Pharmaceuticals in push to develop cancer treatments
Both deals will make use of Volition's Nu.Q technology, which can specifically recognize and target epigenetically modified nucleosomes
VolitionRx announces pricing of underwritten public offering of 3 million shares at a public offering price of $2.00 each
The gross proceeds to Volition from the offering, before deducting the underwriting commissions and other estimated offering expenses payable by Volition, are expected to be $6 million
VolitionRx presents data related to its NETs research at ISTH Congress
The company published a poster presentation entitled "Evaluation and comparison of NETosis biomarkers in sepsis and COVID-19 patients" that showcased the correlation reported between the Nu.Q NETs level and the currently used SOFA score
VolitionRx says Nu.Q NETs test gets CE mark enabling clinical use in over 27 countries across Europe
"NETosis has become a huge focus for medics in recent years, given elevated levels of NETs are associated with poor patient outcomes in a range of diseases, such as COVID-19, but also including sepsis and cancer,” Jake Micallef, chief scien
VolitionRx reports strong 1Q anchored by $10M milestone payment from Heska for Nu.Q Vet Cancer Screening Test
The Austin, Texas-based epigenetics company said it had cash and cash equivalents of around $23.7 million as of March 31, 2022, compared with $20.6 million at the end of December 2021
VolitionRx launches its Nu.Q Vet Cancer Test in Asia through distributor SAGE Healthcare
SAGE is now actively marketing the test and will be processing samples and providing test results from its centralized lab with immediate effect
VolitionRx appoints industry veteran Sharon Ballesteros as its US head of quality and development process
Ballesteros has more than 20 years of experience within the in-vitro diagnostics industry with senior roles at companies such as Siemens Health Diagnostics and Thermo Fisher
VolitionRx makes ‘good progress’ in key areas as it ends 2021 with over $20M in cash
"Volition Veterinary is an exciting, fast-moving part of our business with clear potential to generate significant revenue for the company, initially under our agreements with Heska and SAGE Healthcare, through both milestone payments and o
VolitionRx strikes exclusive $28M deal with Heska Corp to sell its Nu.Q vet cancer screening test
Heska will receive the worldwide rights to sell the test while VolitionRX will get a $10 million upfront payment on signing and up to $18 million based upon near to mid-term milestones
VolitionRx presents study data at ASCO GI 2022 on circulating nucleosomes for detecting colorectal cancer
The studies found that Volition’s flagship Nu.Q assays, when used with the Fecal Immunochemical Test (FIT), can detect colorectal cancer and all high-risk advanced adenomas in symptomatic patients, reducing unnecessary colonoscopies
VolitionRx Limited executes first supply and licensing contract for its Nu.Q Vet Cancer Screening Test in Asia
The contract is with Singapore-based SAGE Healthcare, a leading distributor of premium veterinary products and services in the region
VolitionRx well positioned with $22.9M as it shifts gears to become a commercial company with products
The company is in advanced negotiations with three top veterinary companies and anticipates signing a term sheet for Nu.Q Vet licensing and distribution with one of those parties before the end of 2021
VolitionRx strengthens balance sheet and closes 2Q with $27.9M in cash and cash equivalents
With a balance sheet of $19.4 million as of December 31, 2020, the company continues to manage expenditures carefully with a cash burn rate of about $2 million per month
VolitionRx says Nu.Q NETs assay shows promising results in coronavirus risk stratification
The company has been working with researchers at two NHS Foundation Trusts on coronavirus (COVID-19) studies for which abstracts were released this week
VolitionRx unveils robust balance sheet, progression of its Nu.Q products ahead of US launch in 1Q update
During the quarter, Volition initiated production of Nu.Q product components at scale at its Silver One manufacturing facility in Isnes, Belgium
VolitionRx Limited sees Nu.Q Capture assay paper published in scientific journal
The NuQ platform looks for molecular signatures of cancer by focusing on the nucleosomes — a section of DNA wrapped around a core of proteins — in the blood
VolitionRx appoints industry veterans Kim Nguyen and Richard Brudnick to its board of directors
Nguyen is currently serving as Head of Human Resources for Google Asia Pacific, while Brudnick has held senior positions in a number of pharmaceutical companies
VolitionRx CEO says company in ‘strongest-ever financial position’ to pursue ‘many milestones’
Following a public offering in February, the firm’s cash and equivalents totaled $40 million before deducting expenses incurred so far in 2021
VolitionRx says new data demonstrate Nu.Q's effectiveness in monitoring treatment of Sepsis
The company said an abstract on the findings has been released at a virtual meeting of the International Society for Apheresis
Small-Cap Snapshot: JinkoSolar shares fall after second-quarter earnings miss
VolitionRx shares advance on promising test accuracy for prostate cancer
VolitionRx commences first triage study in Asia, gets ethical approval for final phase of a study in Denmark
The NYSE-listed firm said it has begun an evaluation of its Nu.QTM Colorectal Cancer Triage product in a Taiwanese population of 383 subjects
VolitionRx eyeing launch in Europe of colorectal cancer test next year
The CE Mark will make the blood test potentially saleable in all 28 EU countries.
VolitionRx Ltd set for US$10.6mln cash boost after placing
In September, VolitionRx said it expects to receive European Union CE Marking on its Nu. Q colorectal cancer blood test later this year.
VolitionRx readies for first product launch
A first NuQ blood test will be launched for colorectal cancer later this year in Europe
VolitionRx eyes commercialisation of first cancer test
Chief executive Cameron Reynolds told Proactive: "It's one thing to be a science project. It's another to have products and we are right on the cusp of that.”
VolitionRx gearing up with NUQ market entry with new hire
Cancer diagnostics group VolitionRx Ltd is gearing up for the initial market entry of its NuQ blood tests with the appointment of an experienced marketing executive.
VolitionRx Ltd delighted with European approval for two blood assays
Cancer diagnostics and life sciences group VolitionRx Ltd reached yet another milestone - with the award of CE marks for two of its blood-based tests for detecting colorectal cancer.
VolitionRx Limited raises around US$12.8mln from share offer
Cancer diagnostics group VolitionRx Limited has raised around US$12.8mln from its share placing, which will be used to further the business, including for clinical studies and product commercialisation.
VolitionRx to raise US$12.25mln at modest discount
The company is currently going through the approval process for a European CE mark
VolitionRx pleased with progress in 2015
The NuQ test measures nucleosomes in the bloodstream – an indication that cancer is present.
VolitionRx Ltd hails findings in first non-cancer NUQ study
VolitionRx Ltd has proved its technology's diagnostic potential outside cancer - as it reported positive findings in a pilot study looking at a deadly lung disease.
Risers & Fallers: Providence Resources, MRS, Arria NLG, Stratex Intl, Lancashire Hldgs, WPP
Some significant movers on Thursday at 9.30am, including Stratmin Global and Victoria Oil & Gas..
VolitionRx hails 'best yet' in early colorectal cancer detection
In a study of 430 patients in Denmark, the test accurately detected 75% of colorectal adenomas
VolitionRx set for catalyst-packed 2016, reckons Edison
The stage is set for a catalyst-packed 2016 for cancer diagnostics firm VolitionRx, reckons research house Edison.
Proactive news highlights: Imaginatik, Corero Network, Scancell Holdings and more
Motive Television, VolitionRx and Jersey Oil & Gas were also in the news
VolitionRx's appointment supports strategy to enter US market
Diagnostics specialist VolitionRx has hired a full-time head of US operations as it prepares to introduce its NuQ blood tests for cancer stateside and around the globe.
VolitionRx granted US supportive patent for core technology
VolitionRx's tests are based on the science of nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream – an indication that cancer is present.
Investments and investor services
Proactive news highlights – Robots, web domain deal, tidal power and cancer tests
Making Tuesday’s news highlights: Rex Bionics, VolitionRx, CentralNic, Challenger Acquisitions, Atlantis Resources, fastjet, and several others.
VolitionRx reports encouraging detection rates in colorectal cancer study
A panel test of four NuQ biomarker assays, adjusted for age, detected 91% of colorectal cancer cases
VolitionRx to present at Los Angeles conference
At the conference, David Kratochvil, chief financial officer and treasurer, and Scott Powell, vice president of IR, will outline the company’s business milestones
Trending on Thursday - diamonds, biopharma and tech IPO's
Aside from the Fed and interest rates, what else is trending...?
Archive
Proactive news summary: 88 Energy, accesso, Active Energy, Aminex, Atlantis Res, blur, Fox Marble...
Highlights of the news developments from the growth companies universe
U.S. Risers/Fallers: Lucara Diamond, Lightlake, DARA Biosciences, VolitionRx, AmpliPhi Biosciences
Below are the main news driven share price changes at 10:17 a.m. in New York on Thursday:
VolitionRx tests score highly in lung cancer detection study
Lung cancer is the second most common form and smoking history is the most important of the known and proven risk factors.
Investments and investor services
Proactive highlights - Allergy Therapeutics, Angle, Summit, VolitionRx, Faron Pharma, Camco Clean Energy, Mobile Streams & more
Here we take our daily look at the small cap news highlights of the trading day
VolitionRx granted second patent for nucleosome cancer test
The new patent covers the methods for measuring nucleosome-protein bonds
VolitionRx granted second US patent
VolitionRx (NYSE:VNRX) has been granted a second US patent for its test to detect cancer through changes in nucleosomes.
U.S. Risers/Fallers: Kohl's, Chembio, Cynapsus, Regen, Gogo, Energizer, SinglePoint
Below are the main news driven share price changes at 10:50 a.m. in New York on Thursday:
VolitionRx chief to present at New York and London conferences
Cancer test developer VolitionRx (NYSE:VNRX) revealed that chief executive Cameron Reynolds will at two conferences this month (November) to discuss the business's progress.
Archive
Proactive news summary: Allergy Therapeutics, Berkeley Energy, Forbidden Technologies, Gemfields ...
Pride of place goes to Plethora Solutions, after Jim Mellon's Regent Pacific offered to take it over.
VolitionRx expects final colorectal test results early next year
Initial results from the use of its NuQ test were encouraging.
Archive
Proactive news summary: 88 Energy, Egdon Res, Europa Oil & Gas, Falcon Oil & Gas, Galasys, IMIC ...
Lots of positive news from the oil sector today from places as far afield as Morocco, Alaska and ... er ... Lincolnshire.
VolitionRx records 95% detection rate in second pancreatic study
A second study has validated VolitionRx’s NuQ blood test as a way to potentially detect pancreatic cancer..
VolitionRx: 95% detection in new pancreatic study
Results were similar to a completely separate study of 59 individuals at Lund University in Sweden
VolitionRx's first CE Mark paves way for European clinical sales
Shares in VolitionRx rose in early deals after the life sciences company announced it had received a first CE Mark for a blood-based diagnostic assay, paving the way for clinical sales in Europe.
Investments and investor services
Proactive news highlights including 88 Energy, AFC, Stride Gaming, Gemfields, Xtract, Amphion...
It was a busy day in the small cap world with Gemfields garnering much attention...
VolitionRx hails first US patent as key milestone.
VolitionRx’s tests are based on the science of Nucleosomics, which identifies and measures nucleosomes in the bloodstream.
Investments and investor services
Proactive news summary including shanta Gold, Mariana Resources, Sirius Minerals, SolGold, Globo...
There was a lot of news to get through today in the world of small caps...
VolitionRx takes step towards US market with GSS tie-up
VolitionRx took a step towards commercialising its innovative colorectal cancer tests in the USA........